See more : Gama Explorations Inc. (GAMA.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Bavarian Nordic A/S (BVNRY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bavarian Nordic A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Thermo Fisher Scientific Inc. (TMO.NE) Income Statement Analysis – Financial Results
- ISS A/S (ISFFF) Income Statement Analysis – Financial Results
- OneSpaWorld Holdings Limited (OSW) Income Statement Analysis – Financial Results
- NightDragon Acquisition Corp. (NDAC) Income Statement Analysis – Financial Results
- Shreyas Intermediates Limited (SHREYASI.BO) Income Statement Analysis – Financial Results
Bavarian Nordic A/S (BVNRY)
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.06B | 3.15B | 1.90B | 1.85B | 662.49M | 500.62M | 1.37B | 1.01B | 1.02B | 1.22B | 1.21B | 1.02B | 523.60M | 314.07M | 74.78M | 208.81M | 332.10M | 175.29M | 247.60M | 164.78M | 504.64M | 121.08M | 0.00 |
| Cost of Revenue | 2.46B | 1.45B | 1.33B | 1.20B | 354.76M | 255.12M | 290.62M | 297.79M | 415.14M | 495.08M | 484.71M | 513.55M | 403.39M | 444.47M | 140.10M | 196.66M | 55.12M | 110.80M | 132.23M | 70.25M | 187.19M | 56.45M | 0.00 |
| Gross Profit | 4.60B | 1.70B | 570.32M | 657.29M | 307.73M | 245.50M | 1.08B | 708.95M | 605.42M | 721.73M | 727.80M | 503.08M | 120.21M | -130.40M | -65.32M | 12.15M | 276.99M | 64.50M | 115.37M | 94.53M | 317.45M | 64.62M | 0.00 |
| Gross Profit Ratio | 65.18% | 53.99% | 30.05% | 35.48% | 46.45% | 49.04% | 78.79% | 70.42% | 59.32% | 59.31% | 60.02% | 49.49% | 22.96% | -41.52% | -87.34% | 5.82% | 83.40% | 36.79% | 46.60% | 57.37% | 62.91% | 53.37% | 0.00% |
| Research & Development | 2.35B | 1.18B | 399.16M | 341.42M | 409.28M | 386.30M | 518.41M | 463.17M | 386.81M | 478.93M | 496.61M | 357.44M | 261.72M | 210.83M | 163.98M | 129.65M | 134.96M | 39.28M | 114.38M | 120.44M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 419.85M | 376.02M | 292.92M | 278.15M | 173.42M | 179.96M | 168.06M | 174.21M | 174.79M | 181.02M | 156.99M | 137.76M | 133.40M | 104.58M | 91.48M | 92.04M | -1.57M | -76.37M | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Selling & Marketing | 331.58M | 212.93M | 191.78M | 285.78M | 53.48M | 33.73M | 39.88M | 38.56M | 42.27M | 45.11M | 40.78M | 39.57M | 33.35M | 28.28M | 20.41M | 22.51M | 2.58M | 77.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 751.43M | 588.96M | 484.70M | 563.93M | 226.89M | 213.68M | 207.94M | 212.77M | 217.06M | 226.13M | 197.77M | 177.32M | 166.75M | 132.86M | 111.89M | 92.04M | 1.00M | 819.00K | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -627.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.84M | 206.05M | 228.16M | 45.37M | 120.44M | 60.42M | 59.88M | 71.53M |
| Operating Expenses | 3.11B | 1.77B | 883.86M | 277.70M | 636.18M | 599.98M | 726.34M | 675.94M | 603.87M | 705.06M | 694.38M | 534.76M | 428.48M | 343.69M | 275.87M | 235.53M | 342.01M | 268.26M | 235.14M | 176.85M | 103.41M | 91.27M | 93.48M |
| Cost & Expenses | 5.01B | 3.22B | 2.21B | 1.47B | 990.93M | 855.10M | 1.02B | 973.74M | 1.02B | 1.20B | 1.18B | 1.05B | 831.87M | 788.16M | 415.97M | 432.19M | 397.13M | 379.06M | 367.37M | 247.10M | 290.60M | 147.73M | 93.48M |
| Interest Income | 40.21M | 26.00K | 1.74M | 193.00K | 602.00K | 842.00K | 644.00K | 272.00K | 38.00K | 12.00K | 29.00K | 667.00K | 21.65M | 4.19M | 7.76M | 40.09M | 25.71M | 4.36M | 19.67M | 9.77M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.52M | 119.69M | 152.06M | 177.00M | 18.49M | 14.53M | 5.68M | 7.06M | 6.53M | 6.28M | 6.49M | 7.96M | 9.76M | 13.54M | 17.81M | 40.09M | 2.13M | 2.27M | 16.32M | 4.17M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 553.82M | 399.25M | 387.69M | 344.08M | 57.05M | 41.64M | 106.81M | 44.08M | 43.53M | 44.95M | 46.22M | 56.45M | 53.88M | 49.74M | 49.23M | 48.34M | 40.14M | 17.95M | 15.39M | 18.26M | 12.93K | 5.13M | 3.60M |
| EBITDA | 2.14B | 395.40M | 85.94M | 819.13M | -269.21M | -300.47M | 387.63M | 91.98M | 127.69M | 115.58M | 58.92M | 15.69M | -234.24M | -420.16M | -273.23M | -175.05M | -36.06M | -184.58M | -84.71M | -82.32M | 214.05M | -21.52M | -89.88M |
| EBITDA Ratio | 30.33% | 12.55% | 6.59% | 43.72% | -39.15% | -55.51% | 25.19% | 11.20% | 12.45% | 5.40% | 5.28% | 2.69% | -44.45% | -133.78% | -353.15% | -83.83% | -2.48% | -105.30% | -34.21% | -49.96% | 42.42% | -17.77% | 0.00% |
| Operating Income | 1.50B | -3.85M | -263.31M | 449.62M | -316.43M | -354.48M | 353.19M | 33.01M | 1.55M | 16.68M | 33.42M | -31.68M | -308.26M | -474.09M | -341.18M | -223.39M | -65.03M | -203.77M | -119.77M | -82.32M | 214.04M | -26.65M | -93.48M |
| Operating Income Ratio | 21.28% | -0.12% | -13.87% | 24.27% | -47.76% | -70.81% | 25.78% | 3.28% | 0.15% | 1.37% | 2.76% | -3.12% | -58.87% | -150.95% | -456.23% | -106.98% | -19.58% | -116.24% | -48.37% | -49.96% | 42.41% | -22.01% | 0.00% |
| Total Other Income/Expenses | -19.60M | -240.94M | -119.54M | 618.38M | -16.30M | -2.15M | -50.91M | 6.54M | 76.08M | 47.69M | -27.21M | -17.04M | 11.88M | -9.35M | 10.05M | 26.25M | 25.71M | -1.03M | 3.35M | 5.60M | 3.59M | 936.00K | 2.54M |
| Income Before Tax | 1.48B | -331.61M | -454.43M | 281.98M | -344.75M | -356.64M | 302.28M | 39.55M | 77.63M | 64.36M | 6.20M | -48.73M | -296.38M | -483.44M | -331.13M | -183.30M | -50.49M | -204.79M | -116.42M | -76.72M | 217.63M | -25.71M | -90.94M |
| Income Before Tax Ratio | 21.00% | -10.52% | -23.94% | 15.22% | -52.04% | -71.24% | 22.06% | 3.93% | 7.61% | 5.29% | 0.51% | -4.79% | -56.60% | -153.93% | -442.79% | -87.78% | -15.20% | -116.83% | -47.02% | -46.56% | 43.13% | -21.24% | 0.00% |
| Income Tax Expense | 7.75M | 15.77M | 10.35M | 4.46M | 2.03M | 5.29M | 120.94M | 8.95M | 18.20M | 38.42M | 52.93M | 191.28M | 27.96M | 93.53M | 64.86M | 32.94M | 13.01M | -43.86M | -21.69M | -23.71M | 67.06M | -95.83M | 1.14M |
| Net Income | 1.48B | -347.38M | -464.78M | 277.52M | -346.78M | -361.93M | 181.34M | 30.60M | 59.43M | 25.94M | -46.73M | -240.00M | -268.42M | -389.91M | -266.28M | -150.36M | -59.97M | -158.04M | -94.73M | -53.01M | 150.57M | 70.12M | -92.09M |
| Net Income Ratio | 20.89% | -11.03% | -24.49% | 14.98% | -52.34% | -72.30% | 13.24% | 3.04% | 5.82% | 2.13% | -3.85% | -23.61% | -51.26% | -124.15% | -356.07% | -72.01% | -18.06% | -90.16% | -38.26% | -32.17% | 29.84% | 57.91% | 0.00% |
| EPS | 19.20 | -4.93 | -7.37 | 5.13 | -8.50 | -2.96 | 1.50 | 0.26 | 0.55 | 0.26 | -0.47 | -2.43 | -3.41 | -8.83 | -6.96 | -3.31 | -1.38 | -4.13 | -2.88 | -1.88 | 5.01 | 2.64 | -4.52 |
| EPS Diluted | 19.23 | -4.93 | -7.37 | 5.13 | -8.50 | -2.96 | 1.50 | 0.26 | 0.55 | 0.26 | -0.47 | -2.43 | -3.41 | -8.83 | -6.96 | -3.31 | -1.38 | -4.13 | -2.88 | -1.88 | 5.01 | 2.64 | -4.50 |
| Weighted Avg Shares Out | 76.83M | 70.42M | 63.10M | 54.05M | 40.81M | 122.32M | 119.95M | 114.13M | 105.42M | 99.96M | 98.96M | 98.96M | 78.62M | 44.14M | 38.25M | 45.39M | 43.42M | 38.31M | 32.84M | 28.19M | 30.07M | 26.61M | 20.38M |
| Weighted Avg Shares Out (Dil) | 76.71M | 70.42M | 63.10M | 54.05M | 40.81M | 122.32M | 120.91M | 115.03M | 108.47M | 101.79M | 98.96M | 98.96M | 78.62M | 44.14M | 38.25M | 45.39M | 43.42M | 38.31M | 32.84M | 28.19M | 30.07M | 26.61M | 20.45M |
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, November 30, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
Bavarian Nordic to hold Capital Markets Days in February 2024
COPENHAGEN, Denmark, November 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) will hold a series of capital markets days in February 2024 for investors and analysts across Europe and the U.S.
Bavarian Nordic A/S (BVNKF) Q3 2023 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q3 2023 Earnings Call Transcript November 16, 2023 8:00 AM ET Company Participants Rolf Sass Sorensen - Vice President of Investor Relations Paul Chaplin - President and Chief Executive Officer Henrik Juuel - Executive Vice President,...
US CDC panel recommends Bavarian Nordic's vaccine for adults at risk of mpox
Bavarian Nordic said on Wednesday the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted in favor of recommending the routine use of Jynneos vaccine for adults at risk of mpox.
Bavarian Nordic's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk
COPENHAGEN, Denmark, October 25, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted in favor of recommending the routine use of JYNNEOS®,...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, September 4, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, September 1, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.
Bavarian Nordic A/S (BVNKF) Q2 2023 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q2 2023 Earnings Conference Call August 23, 2023 8:00 AM ET Company Participants Rolf Sass Sorensen - Vice President Investor Relations Paul Chaplin - President and Chief Executive Officer Jean-Christophe May - Executive Vice President, Chief...
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
COPENHAGEN, Denmark, August 6, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today positive topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial ( NCT05072080 ) of its virus-like particle (VLP)-based chikungunya virus vaccine candidate, CHIKV VLP (PXVX0317)...
Bavarian Nordic to discontinue RSV vaccine programme
Denmark-based Bavarian Nordic said on Saturday it was discontinuing its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease from RSV.
Source: https://incomestatements.info
Category: Stock Reports